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Background: The changes in synovial fluid biomarkers after intra-articular injection of hyarulonic acid (IA HA)
remain controversial. We investigate the changes in the properties of synovial fluid (SF) and clinical symptoms
before the first and fifth IA HA.
Methods: A total of 73 patients (73 knees) with symptomatic knee osteoarthritis were treated with five weekly
intra-articular injections of HA and 55 patients (55 knees) were analyzed. The SF total volume, viscosity, and levels
of HA, chondroitin 4-sulfate (C4S), chondroitin 6-sulfate (C6S), keratin sulfate, and interleukin (IL)-6 were measured
before the first and fifth injections. Clinical evaluations were performed using the American Knee Society score
for physician-based outcome measurements and Knee injury and Osteoarthritis Outcome Score for patient-based
outcome measurements before the first and fifth injections.
Results: The SF viscosity and levels of HA were significantly increased, and the total SF volume and levels of
chondroitin 4-sulfate, chondroitin 6-sulfate, and interleukin-6 were significantly decreased. The physician-based
and patient-based outcome scores were improved.
Conclusions: Our findings speculate that HA injections significantly modulate levels of intra articular biomarkers
which may indicate beneficial effect for articular cartilage and synovium membrane.
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Knee osteoarthritis (OA) is a common disease in aging
people. The characteristics of OA are degeneration and de-
struction of the articular cartilage, with secondary induction
of hydrarthrosis and synovitis by inflammatory cytokines
and growth factors from the destroyed cartilage and syn-
ovial membrane [1]. In advanced OA, hyaluronic acid (HA)
is decreased in the synovial fluid (SF) [2], and the SF viscos-
ity and chondroprotective function are also reduced. These
changes cause further destruction of the articular cartilage.
The theoretical basis of intra-articular injection of HA
(IA HA) is to improve the joint lubrication and SF viscosity
[3]. The efficacy of IA HA is controversial in the past ran-
domized control trials or meta-analysis [4-12].The Ameri-
can Academy of Orthopaedic Surgeons stated that IA HA* Correspondence: kusayama@hotmail.co.jp
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in any medium, provided the original work is pis no longer recommended in the 2nd edition of their guide-
line for knee OA treatment published in 2013 [13]. The
Osteoarthritis Research Society International commented
that the treatment appropriateness of IA HA is uncertain in
their guidelines for the management of knee OA [14]. HA
drug for intra-articular injection was produced in Japan at
1987, IA HA was still widely used for treatment of knee
OA to this day and we have confidence in this therapy.
Therefore, the efficacy and safety of IA HA remain contro-
versial between Japan and other countries.
Many biomarkers are reported to be related with this
pathogenesis. Some types of biomarkers reflect cartilage
degeneration, others reflect inflammation condition of
synovium. The destruction of joint cartilage associated
with OA degeneration leads to the release of chondroitin
6-sulfate (C6S), chondroitin 4-sulfate (C4S), and keratin
sulfate (KS) from proteoglycan molecules into the SF,
which can also be measured as biomarkers of jointis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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evaluation of IA HA, because these factors directly re-
flect the states of the articular cartilage and synovial
membrane. Inflammation is one of the factors associated
with OA changes [17,18]. Synovitis, which is secondarily
induced, is related to joint destruction and OA progres-
sion [19]. Inflammatory cytokines are released from the
synovial membrane under the synovitis condition.
Interleukin-1-β (IL-1β), tumor necrosis factor-α (TNF-
α), matrix metalloproteases (MMP-1, MMP-3, MMP13)
are known for proinflamatory mediators [20]. IL-6 is also
one of the inflammatory cytokines that is especially ele-
vated in rheumatoid arthritis [21,22]. IL-6 is also de-
tected in SF from patients with knee OA, and high levels
of IL-6 are associated with the development of OA and
pain severity [23-27]. We measured the IL-6 concentra-
tions as a biomarker for inflammatory reactions in knee
OA treated by IA HA. The first therapeutic purpose of
IA HA is supplementation of the decreased HA concen-
tration and viscosity in SF induced by OA changes, but
few researchers have measured the HA concentration
and viscosity in SF after IA HA [3,28-30]. We evaluated
the HA concentration and viscosity of SF to evaluate the
practical changes in the SF properties after IA HA
treatment.
We performed five weekly IA HA treatments. We
hypothesize that HA has condroprotective effect and in-
hibitory effect for synovitis, and that biomarkers which
indirectly reflect cartilage metabolism and inflammation
condition would be changed after IA HA treatment. No
studies have measured biomarkers of cartilage degener-
ation products, inflammation, and viscosity in SF and
clinical results at the same time. The main purpose of
this study was to investigate the changes in SF viscosity,
HA, C4S, C6S, and KS as cartilage degenerative bio-
markers, IL-6 as an inflammatory biomarker, and also




The study subjects were all patients who fulfilled the
American College of Rheumatology criteria for knee OA
[31] and visited our outpatient clinic between January
2010 and August 2013. The inclusion criteria for the
study were: (1) age above 40 years; (2) radiographic clas-
sification of knee OA of Kellgren–Lawrence (K/L) grade
2 or 3 [32]; and (3) hydroarthrosis detected by clinical
examination. The exclusion criteria were: (1) previous
treatment with IA HA or corticosteroid; (2) opioid or
non-steroidal anti-inflammatory drug administration
within the previous 6 weeks; (3) knee arthritis caused by
rheumatoid arthritis, gout, pseudogout, avascular necro-
sis, injury, or joint infection; and (4) surgical treatmentincluding arthroscopy or high tibial osteotomy. All pa-
tients provided informed consent and agreed to partici-
pate in the study. This study was approved by the ethics
committee of our hospital. Ethical committee approval
number is B1000902020.
Intra-articular injection and sample collection
Patients were treated with five weekly intra-articular in-
jections of 1% HA (low molecular weight: approximately
900 kDa) solution with a dosage of 2.5 ml/injection
(Artz; Seikagaku Corporation, Tokyo, Japan). The SF
samples were collected as much as possible through a
lateral suprapatellar approach using a 21-gauge needle
before each HA injection, and centrifuged at 15,000 × g
for 15 minutes at room temperature. The supernatants
were collected and immediately stored at −80°C until
analysis. The biomarkers in SF were analyzed before the
first and fifth IA HA treatments.
Measurement of joint biomarkers
The C6S and C4S levels in SF were measured by high
performance liquid chromatography according to the
method reported by Shinmei et al. [15]. The SF samples
were diluted 10-fold and subjected to a series of
digestions with chondroitinase ABC and chondroitinase
AC-II (Seikagaku Corporation). The chondroitinase di-
gestions produced the unsaturated disaccharides Δdi-6S
and Δdi-4S from the CS chain structures in C6S and
C4S, respectively. After ultrafiltration of the digested so-
lutions, the levels of Δdi-6S and Δdi-4S in the filtrates
were analyzed, and the area of the peak corresponding
to each unsaturated disaccharide was calculated.
The KS levels in SF were measured by high perform-
ance liquid chromatography according to the method re-
ported by Yamada et al. [33]. The SF samples were
diluted 10-fold and treated with keratanase II (Seikagaku
Corporation) for digestion into two disaccharide iso-
mers, β-galactosyl-(1–4)-6-0-sulfo-N-acetylglucosamine
(L2) and β-6-0-sulfo-galactosyl-(1–4)-6-0-sulfo-N-acetyl-
glucosamine (L4). The concentrations of these disac-
charide isomers were determined and the sum of their
levels was considered to be the KS level. The HA levels
in SF were measured by the Morgan–Elson method
[34]. The SF samples were digested with HAase SD
(Seikagaku Corporation), and the concentration of the
resulting unsaturated disaccharides was determined as
the HA level.
The IL-6 levels in SF were measured by chemilumines-
cent enzyme immunoassay (CLEIA) using mouse mono-
clonal antibodies against recombinant IL-6 (Fujirebio
Inc., Tokyo, Japan) [35]. The assay format was based on
a two-step sandwich CLEIA method. Briefly, 160 μl of
SF was added to 50 μl of a suspension of ferrite micro-
particles coated with a monoclonal antibody against IL-6
Kusayama et al. Journal of Experimental Orthopaedics 2014, 1:16 Page 3 of 9
http://www.jeo-esska.com/content/1/1/16as a solid phase and incubated for 10 minutes at 37°C.
The particles were separated magnetically and washed,
and 250 μl of another monoclonal antibody against IL-6
conjugated with alkaline phosphate was added to the
particles. After incubation at 37°C for 10 minutes, the
particles were washed again. Subsequently, the substrate
solution [AMPPD; 3-(2′-spiroadamantane)-4-methoxy-
4-(3″-phosphoryloxy) phenyl1,2-dioxetane disodium]
was added at 37°C. After incubation for 5 minutes, the
chemiluminescent signals were photon-counted. The assay
was performed using a Lumipulse ƒ system (Fujirebio Inc.),
which is a fully automated CLEIA analyzer.
Measurement of SF viscosity
Viscosity measurements were performed using a cone-
flat plate-type rotational viscometer in the same way
which was reported by the XIV Japanese Pharmacopeia
[36]. SF was introduced to fill the gap between a flat disc
and a cone forming an angle, α (rad). When either the
flat disc or the cone was rotated at a constant angular
velocity or constant torque, the torque acting on the disc
or cone surface rotated by the viscous flow and the cor-
responding angular velocity in the steady state were
measured. The viscosity of the SF, η, was calculated






where η is the viscosity of the liquid (mPa · S), π is the
circumference/diameter ratio, R is the radius of the cone
(cm), α is the angle between the flat disc and the cone
(rad), ω is the angular velocity (rad/s), and T is the torque
acting on the flat disc or cone surface (10−7 N · m).
Radiographs
A weight-bearing anteroposterior knee radiograph was
acquired at the first outpatient clinic visit for assessing
inclusion or exclusion criteria. The degree of knee de-
generation was classified according to the K/L grade
[32]. All patients were graded by two observers (YK and
YA) to avoid differences in incomplete radiographic
grading. The femorotibial angle was measured by one of
the observers (YK).
Evaluation of clinical symptoms
We examined the clinical symptoms before the first and
fifth IA HA treatments. Clinical efficacy was evaluated by
the American Knee Society (AKS) score for physician-
based outcomes and Knee injury and Osteoarthritis Out-
come Score (KOOS) for patient-based outcomes [37,38].
We used the AKS knee and function scores. The KOOS is
a questionnaire that covers five patient-related dimen-
sions: pain; other disease-specific symptoms; activities ofdaily living; sport/recreation functions; and knee-related
quality of life. For each question, five alternatives are pre-
sented, with a score range from 0 to 4 points. The KOOS
questionnaires were filled out by the patients before the
first and fifth IA HA treatments.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows (SPSS, Chicago, IL, USA). Data were expressed
as mean ± standard deviation. Biomarkers were com-
pared using Wilcoxon’s rank-sum test. For correlation
analyses, Spearman’s rank correlation was used. Values
of P < 0.05 were considered significant.
Results
Characteristics of the patients
A total of 73 outpatients (73 knees) with symptomatic
knee OA who had indications for IA HA treatment were
enrolled in this study. Eighteen patients (18 knees) be-
came dry knee before the five weekly IA HA treatments
were completed and they were excluded. Therefore, 55
knees (27 right knees and 28 left knees) were registered.
The study subjects comprised 40 females and 15 males
with a mean age and body mass index of 66.7 ± 9.0 years
and 23.7 ± 2.8 kg/m2, respectively. The K/L grades were
grade 2 in 34 knees, grade 3 in 21 knees. The mean
femorotibial angle was 178.3 ± 3.3°.
Changes in biomarkers after injections
The mean total SF volume, which was 15.9 ml before
the first injection and 8.7 ml before the fifth injection,
was significantly decreased by the IA HA treatments
(P < 0.001) (Figure 1). The mean HA level was signifi-
cantly increased from 1.48 mg/ml to 1.73 mg/ml (P <
0.001). The mean C6S and C4S levels were significantly
decreased from 62.2 nmol/ml to 49.6 nmol/ml (P < 0.05)
and from 18.2 nmol/ml to 15.9 nmol/ml, respectively
(P < 0.05). The mean KS level was not significantly chan-
ged from 6.70 μg/ml to 6.18 μg/ml. The mean IL-6 level
was significantly decreased from 3458 pg/ml to 486
pg/ml (P < 0.05). The mean SF viscosity was significantly
increased from 48.6 mPa · S to68.7 mPa · S (P < 0.001)
(Table 1).
Clinical results
No complications or side effects (e.g. hematoma, infection,
allergic reaction, secondary arthritis) were observed. The
mean range of motion, which was 129° before the first in-
jection and 140° before the fifth injection, was significantly
improved by the IA HA treatments (P < 0.001). The mean
AKS knee score, which was 63 points before the first injec-
tion and 79 points before the fifth injection, was signifi-
cantly improved by the IA HA treatments (P < 0.001). The
mean AKS function score, which was 72 points before the
Figure 1 Time-course changes of mean SF volume before each injection.
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significantly improved by the IA HA treatments (P <
0.001). The mean values of all KOOS subscale scores and
total KOOS score were significantly improved by the IA
HA treatments (P < 0.001) (Table 2).
Correlations among the biomarkers and the clinical scores
Correlation analyses were performed between the bio-
markers (HA, C6S, C4S, KS, IL-6, SF viscosity) and SF
volume and the clinical scores before the first and fifth
injections. Significant positive correlations were ob-
served between the SF viscosity measurement and the
KOOS symptom score (r = 0.466, P = 0.001) before the
fifth injection (Figure 2). A significant negative correl-
ation was observed between the SF volume measure-
ment and the KOOS symptom score (r = −0.449, P =Table 1 Levels of biomarkers and volume in SF before
the first HA injection (week 0) and fifth injection (week 5)
Week 0 Week 5 P value
HA (mg/ml) 1.48 ± 0.40 1.72 ± 0.36 <0.001
C6S (nmol/ml) 62.2 ± 30.4 49.6 ± 18.4 0.001
C4S (nmol/ml) 18.2 ± 6.3 15.9 ± 4.6 0.001
KS (μg/ml) 6.68 ± 4.25 6.18 ± 3.81 0.172
IL-6 (pg/ml) 3458 ± 9094 486 ± 1294 0.013
Viscosity (mPa · S) 48.1 ± 26.7 67.8 ± 35.2 <0.001
SF (ml) 15.9 ± 12.5 8.2 ± 8.7 <0.001
SF: synovial fluid. HA: hyaluronic acid. C6S: chondroitin 6-sulfate. C4S:
chondroitin 4-sulfate. KS: keratin sulfate. IL-6: interleukin-6.
Data are given as mean ± standard deviation.0.001) before the fifth injection (Figure 3). No significant
correlations were found between the other biomarkers
and the clinical scores.
Discussion
This study showed that biomarkers (C4S, C6S, IL-6) and
the SF volume were significantly decreased and HA and
viscosity were significantly increased after IA HA treat-
ment. These improvements of SF properties indicated
that IA HA had potential of affecting for the joint cartil-
age and synovium membrane with knee OA.
The factors that determine the development of knee OA
are degeneration, abrasion, and destruction of the cartil-
age, synovitis associated with these cartilage changes, and
further joint destruction resulting from decreased viscosity
in the SF [1-3]. HA was reported to have inhibitory effects
on cartilage destruction, anti-inflammatory effects, and
supplementary effects for SF viscosity when used to treat
these pathological conditions in OA models in vitro
[39-42]. The present study showed that IA HA treatments
can exert these three effects clinically by evaluating three
types of joint markers.
IA HA caused significant decreases in C6S and C4S,
which were used as biomarkers for cartilage degener-
ation and destruction. CS is bound to the mucopolysac-
charide side chains of proteoglycans, which are the main
components of joint cartilage [43]. Degeneration and
destruction of joint cartilage leads to the release of CS
into the SF [15,16]. CS is also related to the amount of
articular cartilage, and a previous report described that
CS in SF increases at the early stage of OA and
Table 2 Changes in clinical results before the first HA injection (week 0) and fifth injection (week 5)
Week 0 Week 5 P value
Range of motion (degrees) 129 ± 13 140 ± 7 <0.001
AKSKS (points) 63.8 ± 10.8 80.0 ± 10.1 <0.001
AKSFS (points) 72.6 ± 11.8 92.7 ± 7.0 <0.001
KOOS Pain (points) 56.2 ± 17.5 81.3 ± 11.2 <0.001
KOOS Symptoms (points) 62.6 ± 14.8 82.4 ± 12.8 <0.001
KOOS Activity of Daily Living (points) 72.6 ± 17.4 90.3 ± 8.1 <0.001
KOOS Sports (points) 45.1 ± 18.6 73.9 ± 13.6 <0.001
KOOS Quality of Life (points) 35.5 ± 14.8 63.6 ± 16.3 <0.001
Total KOOS score 272.0 ± 73.7 391.6 ± 50.8 <0.001
AKSKS: American Knee Society knee score. AKSFS: American Knee Society function score. KOOS: Knee injury and Osteoarthritis Outcome Score.
Data are given as mean ± standard deviation.
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cartilage degeneration in vitro, as shown in studies using
rabbits [42]. Our subjects were K/L 2 and 3, and they
had residual cartilage. The results of C4S and C6S before
the 1st injection were influenced by the acceleration of
cartilage degeneration. The decrease of C4S and C6S be-
tween before the 1st and 5th injection did not indicate
that residual cartilage was decreased by progression of
OA, but that IA HA suppressed the degeneration of OA.
C6S mainly consists joint cartilage and C4S is distributed
not only cartilage, but also synovium membrane [15], theFigure 2 Correlation between the SF viscosity measurement and thedecrease of C4S and C6S may have the meaning which IA
HA worked for both cartilage and synovium membrane.
Some studies investigated the changes in CS after IA HA.
Kobayashi et al. [45] showed that C6S and C4S were sig-
nificantly decreased after IA HA (molecular weight:
800 kDa) treatments conducted for 16 patients with knee
OA. Similarly, Hasegawa et al. [46] showed that C6S and
C4S were significantly decreased after IA HA (molecular
weight: 900 kDa) treatments conducted for 28 patients
with knee OA. Meanwhile, Sugimoto et al. [47] showed
that there were no significant changes in C6S and C4SKOOS symptom score before the fifth IA HA treatment.
Figure 3 Correlation between the SF volume measurement and the KOOS symptom score before the fifth IA HA treatment.
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ducted for 32 patients with knee OA. These findings dem-
onstrate that there is no consensus about the CS changes
after IA HA. Our study, which involved a larger sample
size than the other studies, revealed significant decreases
in C4S and C6S after IA HA treatments. The decreasing
changes in these biomarkers support the possibility which
IA HA have inhibitory effects of cartilage degeneration
and releasing proteoglycans.
Campion et al. [16] reported that KS is useful bio-
marker for OA. Hasegawa et al. [46 ] showed that KS
was significantly decreased after 5 weekly IA HA treat-
ments conducted 28 patients with knee OA. We also
thought to be useful for measurement of cartilage de-
generation and measured KS. However, we were not able
to show the significant change of KS. We considered
that no significant change of KS also had a meaning.
Biomarkers changes in the SF were not simply attenu-
ated by repeated aspiration from the results of no signifi-
cant change of KS and the decreasing of C4S, C6S and
IL-6. The result of no change of KS is important to show
no attenuation effect.
OA is known to cause inflammatory conditions and sec-
ondary synovitis [19]. IL-1, IL-6, tumor necrosis factor-
alpha, and prostaglandin E2 have been reported to act as
inflammatory biomarkers for OA [48-50]. Beekhuizenet al. [25] compared the levels of 47 cytokines in OA pa-
tients with those in healthy individuals and found that IL-
6 was significantly increased. Similarly, Livshits et al. [26]
found that IL-6 was a significant predictor of radiographic
knee OA. IL-6 has various physiological effects, and causes
destruction of cartilage via its angiogenic effects and acti-
vation of osteoclasts in joints [51,52]. Suppression of IL-6
has the possibility to be effective in protecting against the
cartilage degeneration in OA. Therefore, the levels of IL-6
represent an indicator of the inflammatory conditions
caused by OA and secondary synovitis, and were found to
be significantly decreased after IA HA treatments in the
present study. There are some previous reports about the
levels of IL-6 in SF after IA HA treatment. Bianchi et al.
[53] reported that oral treatment with non-steroidal
anti-inflammatory drugs reduced the levels of IL-6 in SF,
and Gallelli et al. [54] showed similar results. However, the
changing levels of IL-6 in SF after IA HA treatment were
not clear. HA was reported to act on the synovial mem-
brane and inhibit synovitis in dogs [41]. In the present
study, the decreased levels of IL-6 after IA HA treatments
support our hypothesis that IA HA has inhibitory effects
on synovitis and inflammatory reactions. Synovitis in-
creases the SF volume, and we observed a significant de-
crease in the SF volume after IA HA. Our results support
the opinion that HA has anti-inflammatory effects.
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of patients with OA, are indicators of the therapeutic ef-
fects, and our results revealed significant increases in both
factors after IA HA treatments. HA is present in the intra-
articular SF, cartilage, and synovial membrane. The viscosity
and water-holding capacity of HA in SF are responsible for
its function as a shock absorber for the joint and provide
lubrication to the joint [3]. HA infiltrates the synovial mem-
brane and cartilage in vitro and promotes HA synthesis
[41]. There are a few reports regarding the use of HA in ac-
tual clinical practice, which showed that HA supplementa-
tion through IA HA treatment increases viscosity and HA
in SF [28,29,55]. The elimination half-life of HA in the knee
joints of rabbits was reported to be approximately 12 hours,
and injected HA may not remain in the knee joint beyond
1 week [56]. Contrary to these results, HA in SF was found
to be increased after IA HA in this study. Accordingly, we
believe that the increased HA reflects not only the injected
HA but also newly produced HA, which resulted from im-
provement in the condition of the synovial membrane and
cartilage caused by IA HA. Since the increase in SF viscos-
ity is dependent on the HA level, the significant increase in
HA would improve the properties of the SF after IA HA.
The relationships between biomarkers and clinical scores
might enable us to identify the biomarkers that act as prog-
nostic factors and indicate therapeutic effects. To date, re-
searchers have reported several correlations between
biomarkers and clinical scores. Hasegawa et al. [46] found a
negative correlation between C4S or tenascin-C and VAS
scores, while Sugimoto et al. [47] found a positive relation-
ship between C6S or aggrecan and the JOA score. However,
there are also reports that no correlations were found be-
tween biomarkers and clinical scores [45,55]. In the present
study, we investigated the correlations between C6S, C4S,
HA, IL-6, SF viscosity, or SF volume and each item in the
AKS and KOOS scores. Our results indicated a positive
correlation between SF viscosity and KOOS symptom
scores before the fifth injection. No other positive correla-
tions between biomarkers and clinical scores were ob-
served. These results suggest that SF viscosity is related to
the clinical scores. A higher viscosity of SF, which reflects
the theoretical basis of IA HA, was found to be the import-
ant factor for the clinical scores. Additionally, the SF vol-
ume exhibited a negative correlation with the KOOS
symptom scores at the fifth visit after IA HA treatment. No
other negative correlations between biomarkers and clinical
scores were observed. Increased SF volume elevated pres-
sure in the knee joint, worsened range of motion and clin-
ical symptom. The correlation coefficients (r) between
viscosity and KOOS symptom, and SF volume and KOOS
symptom were 0.466 and −0.499. These correlation coeffi-
cients might not be strong. However, these correlations in-
dicate that viscosity and hydrarthrosis are important
parameters for IA HA treatment.Significant improvements were observed in the five
subscales of the KOOS, AKS knee, and AKS function
scores. The KOOS is a patient-based clinical assessment
score, for which the patients themselves input their
subjective symptoms. Meanwhile, the AKS score is a
physician-based clinical assessment score, in which a
physician examines the patient, takes a history, and
evaluates the symptoms. Improvements were observed
in both the patient-based KOOS and physician-based
AKS scores in the present study. The measurements of
two different types of clinical score were more reliable
in researching for efficacy of IA HA.
This study has several limitations. First, the study did
not have a control group, because our hospital decided
that it was ethically inappropriate to create such a control
group. Without control group, we were not able to deny
the possibility of attenuation effect by repeated aspiration.
Second, the follow-up period was short. Although there
were significant changes in joint biomarkers after IA HA
treatments, the results of long-term treatment remain un-
clear. Third, many patients in this study had early and
moderate OA (K/L grade 2 and 3). This is because pa-
tients with terminal OA (K/L grade 4) are indicated for
surgical treatment rather than conservative treatment.
Therefore, there may have been patient bias. Fourth, our
results showed biomarkers of C4S, C6S, KS and IL-6. We
were not able to mention other biomarkers in the SF.
Conclusion
To the best of our knowledge, this is the first report of
simultaneous measurements of HA levels together with
SF viscosity and levels of biomarkers C6S, C4S, KS, and
IL-6 to evaluate the efficacy of IA HA before first and
fifth injection. Also, all of the clinical symptoms were
significantly improved. The changes in the levels of
biomarkers suggested that IA HA treatments may have
cartilage-protective effects, anti-inflammatory effects, and
SF viscosity-replenishing effects.
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